Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

On this episode of Fortune’s Leadership Next podcast, host Diane Brady talks to Eli Lilly chair and CEO Dave Ricks. They ...

The drugmaker has received approval from the Hong Kong government to sell its tirzepatide injections — branded as Mounjaro — ...

Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...

Oct 27 (Reuters) - Eli Lilly (LLY.N), opens new tab expects to start selling its weight-loss drug in Hong Kong as early as the end of this year, Bloomberg News reported, opens new tab on Sunday.

One solution for pharmaceutical giant Eli Lilly and Company comes in the ... a plethora of smart sensors used at US-based firm Lilly’s new $42 million Digital Health Innovation Hub to make ...

Eli Lilly said on Monday it sued three medical spas and online vendors for selling products that claimed to contain tirzepatide, the main ingredient in its popular weight-loss medicine ...

Amgen Inc.'s stock dropped over 7% on Tuesday following revelations about bone density loss in early trials of its ...

The headline trial results will be closely monitored by pharmaceutical industry experts. Shares in Novo Nordisk, which ...

Eli Lilly claims there is no evidence that this compounded drug is safe and effective; the FDA has not approved an oral version of tirzepatide. MangoRx said it “has strong arguments against Eli ...

Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...

Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...